Abstract 834P
Background
Marginal zone lymphoma (MZL) is a relatively common group of inert B-cell non-Hodgkin’s lymphoma (B-NHL) originating from peripheral memory lymphocytes. Some patients cannot achieve complete remission or relapse quickly after standard first-line treatment. Studies have shown that the NF-KB signal pathway in MZL is in an abnormally activated state, while bortezomib is a proteasome inhibitor targeting the NF-KB pathway. This multicenter phase II clinical study evaluated the efficacy and safety of VR-CAP regimen in the first-line treatment of MZL, and explored the best beneficiaries of VR-CAP regimen (rituximab, cyclophosphamide, epirubicin, bortezomib and prednisone).
Methods
The patient received 6 cycles of VR-CAP first-line treatment. Each cycle lasts for 3 weeks, and rituximab (375 mg/m2) is given intravenously on the 0th day, cyclophosphamide (750 mg/m2) and epirubicin (70 mg/m2) are given intravenously on the 1st day, bortezomib (1.3 mg/m2) is given subcutaneously on the 1st and 4th days, and prednisone (100 mg) is given orally on the 1st to 5th days. The primary end point was 2-year progression-free survival (PFS), and the secondary end point was objective response rate (ORR), including complete response (CR) and partial response (PR); Total survival (OS) and security.
Results
At present, 23 patients were enrolled, the median age was 55 years (25-74 years). By February 2023, 15 patients had completed all six courses of treatment; 6 patients completed 4 courses of treatment; Two patients stopped treatment by themselves, and 22 patients could evaluate the curative effect. Sixteen patients (72.7%) and five patients (22.7%) achieved CR/CRu and PR respectively. PFS and OS were 82.2% and 82.0% respectively in two years. Among the 13 patients who have completed all the treatment, the common therapeutic adverse events are anemia (73.9%), gastrointestinal reaction (52.2%), thrombocytopenia (30.4%), pulmonary infection (21.7%), neurotoxicity (8.7%), rituximab-related rash (8.7%).
Conclusions
VR-CAP first-line treatment of lymphoma in the marginal region has a good effect, the objective response rate (ORR) is 95.5%, and the patient is well tolerated. All adverse events are mainly 1-2 grades.
Clinical trial identification
NCT04433156.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18